Activities of ciprofloxacin, levofloxacin, oflxacin and sparfloxacin against speciated coagulase-negative staphylococci sensitive and resistant to fluoroquinolones

International Journal of Antimicrobial Agents

Volumn 9, Issue 2, 1997, Pages 127-130

  Hamilton Miller, J M T ^a   Shah, S ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Coagulase negative staphylococci; Fluoroquinolones; Staphylococcus epidermis; Staphylococcus haemolyticus

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; METICILLIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS;

EID: 0030806062     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00039-3     Document Type: Article

References (13)

1. Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of Clinical Microbiology, 6th ed. Washington: American Society for Microbiology, 1995:282-298.
2. Mulder JG. A simple and inexpensive method for the identification of Staphylococcus epidermidis and Staphylococcus hominis. Eur J Clin Microbiol Infect Dis 1995;14:1052-6.
3. Brumfitt W, Hamilton-Miller JMT, Shah S. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic against Gram-positive bacteria. J Antimicrob Chemother 1992;30A:S29-37.
4. Brumfitt W, Hamilton-Miller JMT. Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin. J Antimicrob Chemother 1993;31:610-2.
5. von Eiff C, Peters G. In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci. J Antimicrob Chemother 1996;38:259-63.
6. Foleno B, Fu KP. In vitro activity of l-ofloxacin against norfloxacin-resistant coagulase-negative staphylococci. Diagn Microbiol Infect Dis 1992;15:557-9.
7. Cormican MG, Jones RN. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria. J Antimicrob Chemother 1995;36:431-4.
8. Thornsberry C, Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infection 1994;22(2):S80-89.
9. Brumfitt W, Hamilton-Miller JMT, Smith GW, Al-Wali W. Comparative trial of norfloxacin and macrocrystalline nitrofurantoin, in the prophylaxis of recurrent urinary tract infection in women. Q J Med 1991;81:811-20.
10. Dahlhoff A. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus Development during therapy and clinical significance. Infection 1994;22(2):S111-121.
11. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994;38:2231-7.
12. Wiedemann B, Heisig P. Mechanisms of quinolone resistance. Infection 1994;22(2):S73-79.
13. Hamilton-Miller JMT, Iliffe A. Antimicrobial resistance in coagulase-negative staphylococci. J Med Microbiol 1985;19:217-26.